{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:38:45Z","timestamp":1774013925383,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00104-025-02423-8","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:22:56Z","timestamp":1768213376000},"page":"276-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oligometastasierung im Gastrointestinaltrakt","Oligometastasis in the gastrointestinal tract"],"prefix":"10.1007","volume":"97","author":[{"given":"Nikolai","family":"Schleu\u00dfner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"M\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"van Hillegersberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane J.","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2423_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman\u00a0S, Weichselbaum\u00a0RR (1995) Oligometastases. J\u00a0Clin Oncol 13:8\u201310","journal-title":"J Clin Oncol"},{"key":"2423_CR2","unstructured":"(2020) S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms. J\u00a0Deutsche Derma Gesell"},{"key":"2423_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes\u00a0A et\u00a0al (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34:10\u201332","journal-title":"Ann Oncol"},{"key":"2423_CR4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"S-E Al-Batran","year":"2017","unstructured":"Al-Batran\u00a0S\u2011E et\u00a0al (2017) The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction\u2014a\u00a0phase\u00a0III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer 17:893","journal-title":"BMC Cancer"},{"key":"2423_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","volume":"9","author":"Q Liu","year":"2024","unstructured":"Liu\u00a0Q et\u00a0al (2024) Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase\u00a02\u00a0trial. Lancet Gastroenterol Hepatol 9:45\u201355","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2423_CR6","doi-asserted-by":"publisher","first-page":"114062","DOI":"10.1016\/j.ejca.2024.114062","volume":"204","author":"TE Kroese","year":"2024","unstructured":"Kroese\u00a0TE et\u00a0al (2024) European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer 204:114062","journal-title":"Eur J Cancer"},{"key":"2423_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/JHC.S290197","volume":"8","author":"K Kim","year":"2021","unstructured":"Kim\u00a0K, Kim\u00a0TH, Kim\u00a0TH, Seong\u00a0J (2021) Efficacy of local therapy for oligometastatic hepatocellular carcinoma: a\u00a0propensity score matched analysis. JHC 8:35\u201344","journal-title":"JHC"},{"key":"2423_CR8","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.3390\/cancers15133467","volume":"15","author":"S Kim","year":"2023","unstructured":"Kim\u00a0S, Lee\u00a0J, Rim\u00a0CH (2023) Local treatment of hepatocellular carcinoma with oligometastases: a\u00a0systematic review and meta-analysis. Cancers 15:3467","journal-title":"Cancers"},{"key":"2423_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jhep.2024.03.003","volume":"81","author":"SH Choi","year":"2024","unstructured":"Choi\u00a0SH, Lee\u00a0B et\u00a0al (2024) Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: a\u00a0phase\u00a0II study. J\u00a0Hepatol 81:84\u201392","journal-title":"J Hepatol"},{"key":"2423_CR10","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s12029-024-01098-4","volume":"55","author":"T Okamoto","year":"2024","unstructured":"Okamoto\u00a0T et\u00a0al (2024) Liver oligometastasis in biliary tract cancer and impact on survival outcomes. J\u00a0Gastrointest Cancer 55:1530\u20131540","journal-title":"J Gastrointest Cancer"},{"key":"2423_CR11","doi-asserted-by":"publisher","first-page":"e033452","DOI":"10.1136\/bmjopen-2019-033452","volume":"9","author":"M Wei","year":"2019","unstructured":"Wei\u00a0M et\u00a0al (2019) Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a\u00a0multicentre, prospective, randomised phase\u00a0III control trial (CSPAC-1). BMJ Open 9:e33452","journal-title":"BMJ Open"},{"key":"2423_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12885-025-13573-7","volume":"25","author":"M Ghadimi","year":"2025","unstructured":"Ghadimi\u00a0M et\u00a0al (2025) Study protocol of the METAPANC trial\u2014intensified treatment in patients with local operable but oligometastatic pancreatic cancer\u2014multimodal surgical treatment versus chemotherapy alone: a\u00a0randomized controlled trial. BMC Cancer 25:208","journal-title":"BMC Cancer"},{"key":"2423_CR13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12885-021-08966-3","volume":"21","author":"F Gebauer","year":"2021","unstructured":"Gebauer\u00a0F et\u00a0al (2021) Study protocol of an open-label, single arm phase\u00a0II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5\u2011fluorouracil\/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer 21:1239","journal-title":"BMC Cancer"},{"key":"2423_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","volume":"16","author":"J Hoeppner","year":"2016","unstructured":"Hoeppner\u00a0J et\u00a0al (2016) ESOPEC: prospective randomized controlled multicenter phase\u00a0III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 16:503","journal-title":"BMC Cancer"},{"key":"2423_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner\u00a0J et\u00a0al (2025) Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N\u00a0Engl J Med 392:323\u2013335","journal-title":"N Engl J Med"},{"key":"2423_CR16","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO-25-00486","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara\u00a0K et\u00a0al (2025) Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase\u00a0III KEYNOTE-585 study. J\u00a0Clin Oncol 43:3152\u20133159","journal-title":"J Clin Oncol"},{"key":"2423_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian\u00a0YY et\u00a0al (2025) Perioperative durvalumab in gastric and gastroesophageal junction cancer. N\u00a0Engl J Med 393:217\u2013230","journal-title":"N Engl J Med"},{"key":"2423_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen\u00a0S et\u00a0al (2024) Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase\u00a0II\/III DANTE\/IKF-s633 trial. J\u00a0Clin Oncol 42:410\u2013420","journal-title":"J Clin Oncol"},{"key":"2423_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang\u00a0Y\u2011J et\u00a0al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a\u00a0phase\u00a03, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"2423_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara\u00a0K et\u00a0al (2025) Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N\u00a0Engl J Med 393:336\u2013348","journal-title":"N Engl J Med"},{"key":"2423_CR21","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara\u00a0K et\u00a0al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a\u00a0multicentre, randomised, double-blind, phase\u00a03\u00a0trial. Lancet 401:1655\u20131668","journal-title":"Lancet"},{"key":"2423_CR22","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah\u00a0MA et\u00a0al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase\u00a03 GLOW trial. Nat Med 29:2133\u20132141","journal-title":"Nat Med"},{"key":"2423_CR23","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke\u00a0H et\u00a0al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a\u00a0double-blind, randomised phase\u00a03\u00a0trial. Lancet Oncol 15:1224\u20131235","journal-title":"Lancet Oncol"},{"key":"2423_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/ijms21030951","volume":"21","author":"J-O Jung","year":"2020","unstructured":"Jung\u00a0J\u2011O, Nienh\u00fcser\u00a0H, Schleussner\u00a0N, Schmidt\u00a0T (2020) Oligometastatic gastroesophageal adenocarcinoma: molecular pathophysiology and current therapeutic approach. Int J Mol Sci 21:951","journal-title":"Int J Mol Sci"},{"key":"2423_CR25","doi-asserted-by":"publisher","first-page":"e2244619","DOI":"10.1001\/jamanetworkopen.2022.44619","volume":"5","author":"Z Shi","year":"2022","unstructured":"Shi\u00a0Z et\u00a0al (2022) Evaluation of concurrent chemoradiotherapy for survival outcomes in patients with synchronous oligometastatic esophageal squamous cell carcinoma. JAMA Netw Open 5:e2244619","journal-title":"JAMA Netw Open"},{"key":"2423_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11912-024-01625-3","volume":"27","author":"TE Kroese","year":"2025","unstructured":"Kroese\u00a0TE, Bronzwaer\u00a0SFC, van Rossum\u00a0PSN, van Laarhoven\u00a0HWM, van Hillegersberg\u00a0R (2025) Oligometastatic esophagogastric cancer: does it exist and how do we treat it? Curr Oncol Rep 27:30\u201336","journal-title":"Curr Oncol Rep"},{"key":"2423_CR27","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.ejso.2015.05.005","volume":"41","author":"T Schmidt","year":"2015","unstructured":"Schmidt\u00a0T et\u00a0al (2015) Surgery in oesophago-gastric cancer with metastatic disease: treatment, prognosis and preoperative patient selection. Eur J Surg Oncol 41:1340\u20131347","journal-title":"Eur J Surg Oncol"},{"key":"2423_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/a-2529-5372","volume":"150","author":"L von Fritsch","year":"2025","unstructured":"von Fritsch\u00a0L, Honselmann\u00a0K, Keck\u00a0T (2025) Leitlinien in K\u00fcrze Updates \u2013 Pankreas. Zentralbl Chir 150:167\u2013169","journal-title":"Zentralbl Chir"},{"key":"2423_CR29","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg\u00a0ZA et\u00a0al (2023) NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI\u00a03): a\u00a0randomised, open-label, phase\u00a03\u00a0trial. Lancet 402:1272\u20131281","journal-title":"Lancet"},{"key":"2423_CR30","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","volume":"33","author":"S Holter","year":"2015","unstructured":"Holter\u00a0S et\u00a0al (2015) Germline BRCA mutations in a\u00a0large clinic-based cohort of patients with pancreatic adenocarcinoma. J\u00a0Clin Oncol 33:3124\u20133129","journal-title":"J Clin Oncol"},{"key":"2423_CR31","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1200\/JCO.19.01890","volume":"38","author":"T Golan","year":"2020","unstructured":"Golan\u00a0T et\u00a0al (2020) Geographic and ethnic heterogeneity of germline BRCA\u00a01 or BRCA\u00a02 mutation prevalence among patients with metastatic pancreatic cancer screened for entry into the POLO trial. J\u00a0Clin Oncol 38:1442\u20131454","journal-title":"J Clin Oncol"},{"key":"2423_CR32","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler\u00a0HL et\u00a0al (2022) Overall survival results from the POLO trial: a\u00a0phase\u00a0III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J\u00a0Clin Oncol 40:3929\u20133939","journal-title":"J Clin Oncol"},{"key":"2423_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan\u00a0T et\u00a0al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N\u00a0Engl J Med 381:317\u2013327","journal-title":"N Engl J Med"},{"key":"2423_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s43018-024-00894-y","volume":"6","author":"A Marabelle","year":"2025","unstructured":"Marabelle\u00a0A et\u00a0al (2025) Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nat Cancer 6:253\u2013258","journal-title":"Nat Cancer"},{"key":"2423_CR35","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1200\/JCO.22.02524","volume":"41","author":"GK Dy","year":"2023","unstructured":"Dy\u00a0GK et\u00a0al (2023) Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non\u2013small-cell lung cancer: 2\u2011year analysis of CodeBreaK 100. J\u00a0Clin Oncol 41:3311\u20133317","journal-title":"J Clin Oncol"},{"key":"2423_CR36","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese\u00a0AM et\u00a0al (2025) Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat Med 31:466\u2013477","journal-title":"Nat Med"},{"key":"2423_CR37","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin\u00a0J et\u00a0al (2022) Anti-tumor efficacy of a\u00a0potent and selective non-covalent KRASG12D inhibitor. Nat Med 28:2171\u20132182","journal-title":"Nat Med"},{"key":"2423_CR38","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.3390\/cancers15245881","volume":"15","author":"IL Wahler","year":"2023","unstructured":"Wahler\u00a0IL, Damanakis\u00a0A, Hokamp\u00a0NG, Bruns\u00a0C, Schmidt\u00a0T (2023) Therapy of locally advanced and oligometastatic pancreatic adenocarcinoma. Cancers 15:5881","journal-title":"Cancers"},{"key":"2423_CR39","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1200\/JCO.24.00081","volume":"42","author":"EB Ludmir","year":"2024","unstructured":"Ludmir\u00a0EB et\u00a0al (2024) Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a\u00a0multicenter, randomized phase\u00a0II trial. J\u00a0Clin Oncol 42:3795\u20133805","journal-title":"J Clin Oncol"},{"key":"2423_CR40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas\u00a0LA et\u00a0al (2023) Personalized RNA neoantigen vaccines stimulate T\u00a0cells in pancreatic cancer. Nature 618:144\u2013150","journal-title":"Nature"},{"key":"2423_CR41","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn\u00a0RS et\u00a0al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N\u00a0Engl J Med 382:1894\u20131905","journal-title":"N Engl J Med"},{"key":"2423_CR42","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro\u00a0B et\u00a0al (2024) Four-year overall survival update from the phase\u00a0III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol 35:448\u2013457","journal-title":"Ann Oncol"},{"key":"2423_CR43","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau\u00a0T et\u00a0al (2025) Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase\u00a03\u00a0trial. Lancet 405:1851\u20131864","journal-title":"Lancet"},{"key":"2423_CR44","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.21873\/anticanres.16720","volume":"43","author":"K Oshita","year":"2023","unstructured":"Oshita\u00a0K et\u00a0al (2023) Outcomes and prognostic analysis of surgical resection for oligometastasis from hepatocellular carcinoma. Anticancer Res 43:5189\u20135196","journal-title":"Anticancer Res"},{"key":"2423_CR45","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"D-Y Oh","year":"2024","unstructured":"Oh\u00a0D\u2011Y et\u00a0al (2024) Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a\u00a0randomised phase\u00a03\u00a0study. Lancet Gastroenterol Hepatol 9:694\u2013704","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2423_CR46","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley\u00a0RK et\u00a0al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet 401:1853\u20131865","journal-title":"Lancet"},{"key":"2423_CR47","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00432-020-03285-9","volume":"146","author":"C Franzese","year":"2020","unstructured":"Franzese\u00a0C et\u00a0al (2020) Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J\u00a0Cancer Res Clin Oncol 146:2289\u20132297","journal-title":"J Cancer Res Clin Oncol"},{"key":"2423_CR48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.adro.2016.10.008","volume":"1","author":"KA Sandler","year":"2016","unstructured":"Sandler\u00a0KA et\u00a0al (2016) Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Adv Radiat Oncol 1:237\u2013243","journal-title":"Adv Radiat Oncol"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-025-02423-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-025-02423-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-025-02423-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:01:32Z","timestamp":1774004492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-025-02423-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2423"],"URL":"https:\/\/doi.org\/10.1007\/s00104-025-02423-8","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Schleu\u00dfner, S.\u00a0M\u00f6nig, F.\u00a0Gebauer, R.\u00a0van Hillegersberg, C.J.\u00a0Bruns und T.\u00a0Schmidt geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}